What are the three treatment approaches for Gleason score 6 prostate cancer confined to the lamina propria (clinical stage T1a‑b)?

Treatment Approaches for Gleason Score 6 Prostate Cancer (T1a-b)

For Gleason score 6 prostate cancer confined to the lamina propria (stage T1a-b), active surveillance is the preferred management strategy, with radical prostatectomy and radiation therapy as alternative definitive treatment options for select patients. 1, 2

The Three Primary Treatment Approaches

1. Active Surveillance (Preferred Option)

Active surveillance should be recommended as the primary management for patients with Gleason 6 disease, particularly those with T1a-b stage. 1, 2 This approach has emerged as the standard of care based on:

• Excellent oncologic outcomes: Disease-specific survival reaches 99-100% at 8-10 years, with metastasis-free survival of 99-100% 1, 2, 3
• Negligible metastatic potential: Contemporary Gleason 6 disease has near-zero risk of metastasis 3, 4
• Quality of life preservation: Avoids treatment-related morbidity including erectile dysfunction (80% with surgery), urinary incontinence (49% with surgery), and bowel complications 1

Monitoring protocol includes: 1, 2

• PSA testing every 3-6 months
• Digital rectal examination every 6-12 months
• Confirmatory biopsy within 6-12 months of diagnosis
• Subsequent biopsies every 1-4 years depending on protocol

Triggers for intervention: 1, 2

• Gleason grade progression on biopsy
• PSA doubling time <3 years
• Increased number or extent of positive cores
• Clinical progression on examination

2. Radical Prostatectomy

Radical prostatectomy is an effective treatment option for T1a-b Gleason 6 disease, particularly for younger patients with life expectancy >10 years who prefer definitive treatment after informed discussion. 1

• Oncologic efficacy: Provides excellent cancer control for localized disease 1, 5
• Appropriate for: Patients with T1a, T1b, T1c, or T2 disease who desire immediate definitive therapy 1
• Surgical approach: Should include pelvic lymph node dissection if predicted probability of lymph node metastasis ≥2% 1

Critical adverse effects to counsel patients about: 1

• Erectile dysfunction: 80% of patients
• Urinary incontinence: 49% of patients
• Perioperative complications
• Recovery time and impact on quality of life

3. Radiation Therapy

Radiation therapy (external beam or brachytherapy) represents the third treatment option for Gleason 6 T1a-b disease. 1, 6

External beam radiation therapy (EBRT): 1, 6

• Minimum dose of 70 Gy recommended
• 3D-CRT/IMRT with daily image guidance preferred
• For Gleason 6 disease, short-term androgen deprivation therapy (4-6 months) is optional, not required 1

Brachytherapy: 1, 5

• Can be used as monotherapy for low-risk disease
• Iodine-125 or Palladium-103 isotopes are standard 1
• Dosimetric planning is mandatory 1
• Four-year biochemical freedom from failure: 91% for low-risk patients 5

Radiation-related adverse effects: 1

• Obstructive urinary symptoms: 44% of patients
• Radiation proctitis: 1-5% (grade 1-2)
• Sexual dysfunction: 45% of patients
• Bowel complications

Critical Decision-Making Algorithm

For patients with life expectancy <10 years: Watchful waiting or active surveillance is most appropriate, as treatment-related morbidity outweighs potential benefit 1

For patients with life expectancy >10 years: 1, 2

1. First-line recommendation: Active surveillance (Strong recommendation, Grade A evidence) 1
2. Consider definitive treatment if: Patient preference after shared decision-making, anxiety about untreated cancer, or progression on surveillance 1, 2
3. Choose between surgery vs. radiation based on: Patient age, baseline urinary/sexual/bowel function, comorbidities, and patient values regarding side effect profiles 1

Important Caveats

Do not confuse T1a-b with higher-risk features: 7

• T1a disease with Gleason score ≥5 has higher progression risk and may warrant more aggressive treatment 7
• The 2005 ISUP revision made Gleason 6 definition more restrictive; contemporary Gleason 6 has better prognosis than historical series 3, 8

Avoid these common pitfalls: 6

• Do not use androgen deprivation therapy as monotherapy for localized Gleason 6 disease—it does not improve survival 6
• Do not omit confirmatory biopsy in active surveillance protocols—69% of biopsy Gleason 6 cases are upgraded at surgery 4
• Do not assume all T1a disease is indolent—Gleason score ≥5 correlates with progression 7

Watchful waiting differs from active surveillance: 1

• Watchful waiting involves less aggressive monitoring with treatment only for symptomatic progression or metastases 1
• Active surveillance involves intensive monitoring with curative intent intervention if disease progresses 1
• For T1a-b Gleason 6 disease with life expectancy >10 years, active surveillance is preferred over watchful waiting 1